Vitamin D does not improve the metabolic health of patients with chronic kidney disease stage 3-4: A randomized controlled trial

Nephrology

Volumn 18, Issue 1, 2013, Pages 26-35

  Petchey, William G ^a,b   Hickman, Ingrid J ^b   Prins, Johannes B ^b,c   Hawley, Carmel M ^a,b   Johnson, David W ^a,b   Isbel, Nicole M ^a,b  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c MATER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

cholecalciferol; chronic kidney disease; insulin resistance; randomized controlled trial; vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ADIPOCYTOKINE; C REACTIVE PROTEIN; CALCIUM; COLECALCIFEROL; GLUCOSE; HEMOGLOBIN A1C; INTERLEUKIN 1BETA; INTERLEUKIN 6; PHOSPHATE; PLACEBO; SERUM ALBUMIN; TUMOR NECROSIS FACTOR ALPHA;

AGED; ARTICLE; BODY FAT; BODY MASS; BODY WEIGHT; CALCIUM BLOOD LEVEL; CALORIMETRY; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FAT FREE MASS; FAT MASS; FEMALE; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY FUNCTION; LIPID OXIDATION; MALE; METABOLIC PARAMETERS; METABOLISM; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; PATIENT COMPLIANCE; PHOSPHATE BLOOD LEVEL; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENOVASCULAR HYPERTENSION; RESPIRATORY QUOTIENT; SYSTOLIC BLOOD PRESSURE; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; WAIST CIRCUMFERENCE;

AGED; CHOLECALCIFEROL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC DISEASES; RENAL INSUFFICIENCY, CHRONIC; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; VITAMINS;

EID: 84872837106     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2012.01662.x     Document Type: Article

References (51)

1. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial. Lancet 2011; 377: 2181-2192.
2. Johnson DW, Craven AM, Isbel NM,. Modification of cardiovascular risk in hemodialysis patients: An evidence-based review. Hemodial. Int. 2007; 11: 1-14.
3. Kaisar MO, Isbel NM, Johnson DW,. Recent clinical trials of pharmacologic cardiovascular interventions in patients with chronic kidney disease. Rev. Recent Clin. Trials 2008; 3: 79-88.
4. Pilz S, Iodice S, Zittermann A, Grant WB, Gandini S,. Vitamin D status and mortality risk in CKD: A meta-analysis of prospective studies. Am. J. Kidney Dis. 2011; 58: 374-382.
5. LaClair RE, Hellman RN, Karp SL, et al. Prevalence of calcidiol deficiency in CKD: A cross-sectional study across latitudes in the United States. Am. J. Kidney Dis. 2005; 45: 1026-1033.
6. Chonchol M, Scragg R,. 25-Hydroxyvitamin D, insulin resistance, and kidney function in the Third National Health and Nutrition Examination Survey. Kidney Int. 2007; 71: 134-139.
7. Petchey WG, Howden EJ, Johnson DW, Hawley CM, Marwick T, Isbel NM,. Cardiorespiratory fitness is independently associated with 25-hydroxyvitamin D in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2010; 6: 512-518.
8. Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ,. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am. J. Clin. Nutr. 2003; 77: 204-210.
9. Vieth R, Chan PC, MacFarlane GD,. Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. Am. J. Clin. Nutr. 2001; 73: 288-294.
10. Charlson ME, Pompei P, Ales KL, MacKenzie CR,. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J. Chronic Dis. 1987; 40: 373-383.
11. Australian Institute of Health and Welfare (AIHW). The Active Australia Survey: A guide and manual for implementation, analysis and reporting. Canberra; 2003. Report No.: CVD 22.
12. DeFronzo RA, Tobin JD, Andres R,. Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am. J. Physiol. 1979; 237: E214-223.
13. Frayn KN,. Calculation of substrate oxidation rates in vivo from gaseous exchange. J. Appl. Physiol. 1983; 55: 628-634.
14. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. 2003; 42 (4 Suppl 3): S1-201.
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC,. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
16. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann. Intern. Med. 2006; 145: 247-254.
17. Ferrannini E, Mari A,. How to measure insulin sensitivity. J. Hypertens. 1998; 16: 895-906.
18. Sechi LA, Catena C, Zingaro L, Melis A, De Marchi S,. Abnormalities of glucose metabolism in patients with early renal failure. Diabetes 2002; 51: 1226-1232.
19. Kautzky-Willer A, Pacini G, Barnas U, et al. Intravenous calcitriol normalizes insulin sensitivity in uremic patients. Kidney Int. 1995; 47: 200-206.
20. DeFronzo RA, Alvestrand A, Smith D, Hendler R, Hendler E, Wahren J,. Insulin resistance in uremia. J. Clin. Invest. 1981; 67: 563-568.
21. Castellino P, Solini A, Luzi L, et al. Glucose and amino acid metabolism in chronic renal failure: Effect of insulin and amino acids. Am. J. Physiol. 1992; 262 (2 Pt 2): F168-176.
22. Eidemak I, Feldt-Rasmussen B, Kanstrup IL, Nielsen SL, Schmitz O, Strandgaard S,. Insulin resistance and hyperinsulinaemia in mild to moderate progressive chronic renal failure and its association with aerobic work capacity. Diabetologia 1995; 38: 565-572.
23. Mak RH,. 1,25-Dihydroxyvitamin D3 corrects insulin and lipid abnormalities in uremia. Kidney Int. 1998; 53: 1353-1357.
24. Jorde R, Figenschau Y,. Supplementation with cholecalciferol does not improve glycaemic control in diabetic subjects with normal serum 25-hydroxyvitamin D levels. Eur. J. Nutr. 2009; 48: 349-354.
25. Witham MD, Dove FJ, Dryburgh M, Sugden JA, Morris AD, Struthers AD,. The effect of different doses of vitamin D(3) on markers of vascular health in patients with type 2 diabetes: A randomised controlled trial. Diabetologia 2010; 53: 2112-2119.
26. Patel P, Poretsky L, Liao E,. Lack of effect of subtherapeutic vitamin D treatment on glycemic and lipid parameters in Type 2 diabetes: A pilot prospective randomized trial. J. Diabetes 2010; 2: 36-40.
27. Borissova AM, Tankova T, Kirilov G, Dakovska L, Kovacheva R,. The effect of vitamin D3 on insulin secretion and peripheral insulin sensitivity in type 2 diabetic patients. Int. J. Clin. Pract. 2003; 57: 258-261.
28. Parekh D, Sarathi V, Shivane VK, Bandgar TR, Menon PS, Shah NS,. Pilot study to evaluate the effect of short-term improvement in vitamin D status on glucose tolerance in patients with type 2 diabetes mellitus. Endocr. Pract. 2010; 16: 600-608.
29. Nikooyeh B, Neyestani TR, Farvid M, et al. Daily consumption of vitamin D- or vitamin D + calcium-fortified yogurt drink improved glycemic control in patients with type 2 diabetes: A randomized clinical trial. Am. J. Clin. Nutr. 2011; 93: 764-771.
30. von Hurst PR, Stonehouse W, Coad J,. Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient-a randomised, placebo-controlled trial. Br. J. Nutr. 2010; 103: 549-555.
31. Nagpal J, Pande JN, Bhartia A,. A double-blind, randomized, placebo-controlled trial of the short-term effect of vitamin D3 supplementation on insulin sensitivity in apparently healthy, middle-aged, centrally obese men. Diabet. Med. 2009; 26: 19-27.
32. Grimnes G, Figenschau Y, Almas B, Jorde R,. Vitamin D, insulin secretion, sensitivity, and lipids: Results from a case-control study and a randomized controlled trial using hyperglycemic clamp technique. Diabetes 2011; 60: 2748-2757.
33. Mak RH,. Amelioration of hypertension and insulin resistance by 1,25-dihydroxycholecalciferol in hemodialysis patients. Pediatr. Nephrol. 1992; 6: 345-348.
34. Mak RH,. Intravenous 1,25 dihydroxycholecalciferol corrects glucose intolerance in hemodialysis patients. Kidney Int. 1992; 41: 1049-1054.
35. Quesada JM, Martín-Malo A, Santiago J, et al. Effect of calcitriol on insulin secretion in uraemia. Nephrol. Dial. Transplant. 1990; 5: 1013-1017.
36. Allegra V, Luisetto G, Mengozzi G, Martimbianco L, Vasile A,. Glucose-induced insulin secretion in uremia: Role of 1 alpha,25(HO)2-vitamin D3. Nephron 1994; 68: 41-47.
37. Türk S, Yeksan M, Tamer N, Gürbilek M, Erdogan Y, Erkul Ï,. Effect of 1,25 (OH)2 D3 treatment on glucose intolerance in uraemia. Nephrol. Dial. Transplant. 1992; 7: 1207-1212.
38. Khajehdehi P, Taheri S,. Effect of oral calcitriol pulse therapy on the lipid, calcium, and glucose homeostasis of hemodialysis-patients: Its safety in a combination with oral calcium carbonate. J. Ren. Nutr. 2003; 13: 78-83.
39. Lin SH, Lin YF, Lu KC, et al. Effects of intravenous calcitriol on lipid profiles and glucose tolerance in uraemic patients with secondary hyperparathyroidism. Clin. Sci. (Lond) 1994; 87: 533-538.
40. Gunal AI, Celiker H, Celebi H, Ustundag B, Gunal SY,. Intravenous alfacalcidol improves insulin resistance in hemodialysis patients. Clin. Nephrol. 1997; 48: 109-113.
41. Lamb EJ, Fluck RJ, Venton TR, Woodhead JS, Raine AE, Dawnay AB,. Effects of parathyroid hormone and 1,25(OH2)D3 on protein glycation in moderate uraemia. Nephron 1996; 74: 295-300.
42. Strõzecki P, Kretowicz M, Odrow-Sypniewska G, Manitius J,. The influence of intravenous 1,25(OH)2D3 therapy on glucose metabolism in hemodialyzed patients with secondary hyperparathyroidism. Ren. Fail. 2004; 26: 345-348.
43. Procopio M, Borretta G,. Derangement of glucose metabolism in hyperparathyroidism. J. Endocrinol. Invest. 2003; 26: 1136-1142.
44. Rigalleau V, Gin H,. Carbohydrate metabolism in uraemia. Curr. Opin. Clin. Nutr. Metab. Care 2005; 8: 463-469.
45. Yki-Jarvinen H,. Role of insulin resistance in the pathogenesis of NIDDM. Diabetologia 1995; 38: 1378-1388.
46. Billaudel B, Barakat L, Faure-Dussert A,. Vitamin D3 deficiency and alterations of glucose metabolism in rat endocrine pancreas. Diabetes Metab. 1998; 24: 344-350.
47. Starikovich LS, Aragon GA, Vernikovska YI, Vigovska TV, Veliky MM,. Effect of a vitamin D3-based nutritional supplement ('Videchol') on carbohydrate metabolism of rats following chronic low dose-rate irradiation. J. Radiol. Prot. 2001; 21: 269-276.
48. van den Bout-van den Beukel CJ, van den Bos M, Oyen WJ, et al. The effect of cholecalciferol supplementation on vitamin D levels and insulin sensitivity is dose related in vitamin D-deficient HIV-1-infected patients. HIV Med. 2008; 9: 771-779.
49. Trirogoff ML, Shintani A, Himmelfarb J, Ikizler TA,. Body mass index and fat mass are the primary correlates of insulin resistance in nondiabetic stage 3-4 chronic kidney disease patients. Am. J. Clin. Nutr. 2007; 86: 1642-1648.
50. Manolescu B, Stoian I, Atanasiu V, Busu C, Lupescu O,. Review article: The role of adipose tissue in uraemia-related insulin resistance. Nephrology (Carlton) 2008; 13: 622-628.
51. Nerpin E, Riserus U, Ingelsson E, et al. Insulin sensitivity measured with euglycemic clamp is independently associated with glomerular filtration rate in a community-based cohort. Diabetes Care 2008; 31: 1550-1555.